chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Got sick with the last booster; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non-HCP), Program ID: The reporter is the patient.  An elderly female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete; unknown manufacturer), for COVID-19 immunization. The following information was reported: ILLNESS (non-serious), outcome "unknown", described as "Got sick with the last booster".  Additional information: The patient got sick with the last booster and was sick of being scared of COVID.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Pt experienced headaches, eye movement pain and congestion. Symptoms began approximately 2 weeks post vax and continued as of the time of this report. Pt was treated with Bactrim, Medrol, Tylenol, Sudafed.
Received Flu vaccine on 11/22/02 and has bruise and swelling. She used ice packs. No medical care required.
notice small red raised area which has been very itchy; notice small red raised area which has been very itchy; had soreness at the injection site with touch after receiving the booster dose; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (had soreness at the injection site with touch after receiving the booster dose), VACCINATION SITE ERYTHEMA (notice small red raised area which has been very itchy) and VACCINATION SITE PRURITUS (notice small red raised area which has been very itchy) in an 85-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 051F21A, 012L20A and 012L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Nov-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VACCINATION SITE PAIN (had soreness at the injection site with touch after receiving the booster dose). On 06-Nov-2021, the patient experienced VACCINATION SITE ERYTHEMA (notice small red raised area which has been very itchy) and VACCINATION SITE PRURITUS (notice small red raised area which has been very itchy). At the time of the report, VACCINATION SITE PAIN (had soreness at the injection site with touch after receiving the booster dose), VACCINATION SITE ERYTHEMA (notice small red raised area which has been very itchy) and VACCINATION SITE PRURITUS (notice small red raised area which has been very itchy) outcome was unknown.            No concomitant medications were given by the reporter. No Treatment information were provided by the reporter.
This case was reported by a nurse via call center representative and described the occurrence of seizure in a 22-year-old male patient who received HAVRIX (batch number TB995, expiry date 25th October 2020). On 9th April 2018, the patient received the 1st dose of HAVRIX .5 ml. On 9th April 2018, immediately after receiving HAVRIX, the patient experienced seizure (serious criteria GSK medically significant) and passed out (serious criteria GSK medically significant). In April 2018, the patient experienced dizziness. In April 2018, the outcome of the seizure and passed out were recovered/resolved. On an unknown date, the outcome of the dizziness was unknown. The reporter considered the seizure, passed out and dizziness to be related to HAVRIX. Additional details were provided as follows: The case was reported by the registered nurse (RN). The patient received HAVRIX in left deltoid. Later on the day of vaccination in the evening, the patient had another seizure and went to the urgent care and they stated that there was no way he could have had two seizures from the HAVRIX vaccine. The patient was also dizzy.
Arm swelling; Burning in arm; Hot to touch arm; Felt like bees were stinging; Itchiness; Hard to lift arm; Pain at the injection sites; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (Arm swelling), BURNING SENSATION (Burning in arm), FEELING HOT (Hot to touch arm), PAIN (Felt like bees were stinging) and PRURITUS (Itchiness) in a 36-year-old female patient who received mRNA-1273 (batch no. 0121L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 18-Jan-2021, the patient received first dose of mRNA-1273 (Intramuscular) 1 dosage form. On 18-Jan-2021, the patient experienced VACCINATION SITE PAIN (Pain at the injection sites). On 20-Jan-2021, the patient experienced PERIPHERAL SWELLING (Arm swelling), BURNING SENSATION (Burning in arm), FEELING HOT (Hot to touch arm), PAIN (Felt like bees were stinging), PRURITUS (Itchiness) and HYPOKINESIA (Hard to lift arm). On 22-Jan-2021, HYPOKINESIA (Hard to lift arm) had resolved. On 27-Jan-2021, PERIPHERAL SWELLING (Arm swelling), BURNING SENSATION (Burning in arm), FEELING HOT (Hot to touch arm), PAIN (Felt like bees were stinging) and PRURITUS (Itchiness) had resolved. At the time of the report, VACCINATION SITE PAIN (Pain at the injection sites) had resolved.        For mRNA-1273 (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication was not reported.  Treatment information was not provided.
Left arm swelling and diffuse erythema from shoulder to elbow. Home treatment with diphenhydramine and ibuprofen. Symptoms began about 24 hrs after injections.
Patient received Meningococcal Vaccine (Manactra) and immediately after experienced dizziness, difficulty breathing and weakness.  Later the same evening (approximately 2 hours after receiving the vaccine) patient experienced limb weakness of both arms and legs and was unable to lift anything or walk. Patient was taken to doctor visit to follow up on reaction.
Pt's complaining she cant raise (L) arm and has c/o soreness and itching on upper (L) arm. Pt is able to move fingers, has sl amt of swelling on upper (L) arm. (L) arm sl warm to touch, no redness noted. Has a circular raised area midway on (L) forearm approx 4 inches down from shoulder. Circular raised area measuring approx 2 inches x 2 inches Informed pt to see MD.
Pt. presented to clinic with swelling redness and warmth at the injection site. No drainage noted Pt injection site. Pt. afebrile.
Mother stated the child developed a fever of 105 degrees between 2-3 pm on 10/25/16. She was accessed at the medical center and no problem identified per mother.
I had an average reaction to first shot; Had medium sized fatigue; Headache; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (I had an average reaction to first shot), FATIGUE (Had medium sized fatigue) and HEADACHE (Headache) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (I had an average reaction to first shot), FATIGUE (Had medium sized fatigue) and HEADACHE (Headache). At the time of the report, VACCINATION COMPLICATION (I had an average reaction to first shot), FATIGUE (Had medium sized fatigue) and HEADACHE (Headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant product information was provided. No treatment information was provided.   This case was linked to MOD-2021-374716 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 03-Nov-2021: Follow up received contains Patient details and event .
Unable to wake up for 48 hours, stressed out and short temper. Plus I've been exposed to covid-19 at work numerous times and probably had it shortly before or during the shot. No course of action was taken after numerous people were diagnosed with covid-19 at my place of work. UCSD on campus
Per Pt's mother, child had itching, pain & swelling in area where shot was given on 7/31/08 around 12:00PM.  Pt's mother stated she gave him BENADRYL and it did not help.
Fine pruritic rash over neck, check and upper back.; This is a spontaneous report from a contactable consumer or other non hcp.  A 19-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: solution for injection), via an unspecified route of administration, administered in left arm on 13Feb2021 16:30 (age at vaccination 19-year-old, Batch/Lot Number: EL9267) as single dose for COVID-19 immunisation. Medical history reported as none. Patient was not pregnant. The patient's concomitant medications were not reported. The patient experienced fine pruritic rash over neck, check and upper back on 15Feb2021 20:00. Therapeutic measures were taken as result of fine pruritic rash over neck, check and upper back. Patient received treatment as Benadryl PO and topical. No other vaccine in four weeks and no other medications in two weeks. Patient has no known drug allergies. No COVID prior vaccination and no COVID tested post vaccination. The outcome of event was not recovered.  Follow-up attempts are completed. No further information is expected.
Palpitations & Tachycardia  Narrative:  The evening of the injection the patient experienced palpitations and a heart rate 134. Patient experienced the same the next night. Today there is mild soreness at the injection site. No prior cardiac or thyroid history. Patient does have a history of asthma.
This spontaneous report was received from a nurse practitioner refers to a patient of unknown age and gender. Medical history was not reported. The nurse practitioner informed that on 09-SEP-2014 the patient was inadvertently vaccinated with ad dose of PNEUMOVAX 23 lot # J004080, expiration date: 22-AUG-2014, intramuscular (dosage was not reported), which expired on 22-AUG-2014. No adverse effects reported. Additional information has been requested.
Patient is currently unable to rotate arm. She claims that it hurts when she drives and in general has a lot of pain associated with injury. Patient is currently doing cold compresses and starting ALEVE to help ease pain. Will follow up with pharmacy in 5-7 days.
my thinking was off on that because it takes two weeks to develop immunity; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient. A female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. Relevant medical history included: "cold" (unspecified if ongoing); "panicked" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Tetanus shot, for immunization. The following information was reported: THINKING ABNORMAL (non-serious), outcome "unknown", described as "my thinking was off on that because it takes two weeks to develop immunity". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Patient was asking if the shape of the spike protein produced by the vaccine can prevent blood flow and lead to lots of tiny blood clots. Patient states her doctor told her that humans naturally have lots of cells with proteins on the surface. Patient asking if it is possible for the mRNA in the vaccine to malfunction and not be broken down after producing a spike protein and then circulate in the body forever and keep making spike proteins. Patient asking how long the vaccine is effective and if the antibodies circulate out of the body over time causing protection to diminish. Patient states, she don't do vaccines really ever. She was not an anti-vaxxer. She have taken a tetanus shot. But it was out of the ordinary for her to do vaccines. She developed a cold a while back and panicked a little. And got tested for Covid-19 and it was negative, but the next day she went and got the first dose of the Pfizer BioNTech Covid-19 Vaccine hoping she would develop antibodies immediately in case the cold turned into Covid-19, but it never did. She also realized her thinking was off on that because it takes two weeks to develop immunity. But she had such a problem mentally with the vaccine that she couldn't bring herself to get the second dose. She was hoping she didn't mess anything up though. Patient asking what negative effects could come from not getting the second dose of the Pfizer BioNTech Covid-19 Vaccine after getting the first dose.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
COVID 19; COVID 19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 24-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 17Jan2022 as dose 4 (booster), single (Lot number: F51614) at the age of 23 years for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Myasthenia gravis" (unspecified if ongoing). There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Negative, notes: Day 10 negative test; Positive, notes: Day 11 positive test. Therapeutic measures were taken as a result of covid-19.  Clinical course: No other medication in 2 weeks. Patient received Anti-viral treatment for COVID-19 with Paxlovid from 28May2022 to 02Jun2022.
Incomplete dose administered/Needle leakage (needle loose at administration); This case was reported by a pharmacist via call center representative and described the occurrence of incomplete dose administered in a 54-year-old female patient who received Herpes zoster (Shingrix) (batch number 23E5G, expiry date 11th February 2024) for prophylaxis.   On 28th November 2022, the patient received the 1st dose of Shingrix. On 28th November 2022, unknown after receiving Shingrix, the patient experienced incomplete dose administered. On an unknown date, the outcome of the incomplete dose administered was unknown.   Additional Information: GSK receipt date: 28-Nov-2022 Reporter's comment: The report was not shared because the reporter mentioned that the needle was loose at the moment of administration and that could be the leakage reason.  For the exposure via skin contact, it was not mentioned during the call. The reporter asked to remain anonymous and denied follow-up Did not consent to follow-up. Additional supportive information: A dose of Shingrix had been administered to a patient, but due to needle leakage the dose was incomplete, which led to incomplete dose administered.
GAVE INJECTION FOR DTAP, HIB, VARICELLA IN R LEG. THEN GAVE INJECTION FOR HEP A IN L LEG.  LEFT LEG IMMEDIATELY BEGAN HAVING A RASH THAT WORKED DOWNWARD TOWARDS HIS ANKLE THERE WAS A RASH NO WHERE ELSE ON BODY.  AFTER ABOUT 5 MINUTES RASH BEGAN TO FADE.
No additional AE reported; Inbound call from nurse who reports an additional (3rd) dose of PROQUAD was accidentally administered to a patient. Product administered 21AUG2023. Patient was 11 years old and had already received first and second dose per dosing schedule in PI. No; This spontaneous report was received from a nurse and referred to an 11-year-old patient of unknown gender. The patient's medical history, concurrent conditions, concomitant therapies and drug reaction/allergies were not reported. On unknown dates, the patient had already vaccinated with the 1st, 2nd dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA) (PROQUAD) injection, administered for prophylaxis (strength, dose, lot #, expiry date and route of administration were not provided) per dosing schedule in product information (PI).  On 21-AUG-2023, an additional (3rd) dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA) (PROQUAD) (0.5 milliliter; strength, lot #, expiry date and route of administration were not provided) was accidentally administered to the patient (Extra dose administered). No additional adverse event details available.
Janssen COVID-19 Vaccine EUA Sloughing of skin of roof of mouth - has pealed off 3 times in 2.5 weeks white bumps on tongue - as if some taste buds have died Sensitivity of inner lips to acidic foods and mouthwash
Herpes zoster pain and rash, C2-C4 cm Right; began < 24 hr after Zostavax
Rebound mild symptoms of fever, congestion malaise starting  approximately 1 week after completing paxlovid.; Rebound mild symptoms of fever, congestion malaise starting  approximately 1 week after completing paxlovid.; This is a spontaneous report received from a non-contactable reporter(s) (Physician).  A 65-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported.  The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Rebound mild symptoms of fever, congestion malaise starting  approximately 1 week after completing paxlovid.". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Treatment of covid-19. Therapeutic measures were taken as a result of vaccination failure, covid-19.  Additional Information: Rebound mild symptoms of fever, congestion malaise starting approximately 1 week after completing paxlovid  Follow-up attempts are completed. No further information is expected.; Sender's Comments: Based on available information , there is reasonable possibility of causal association between the events Vaccination Failure and COVID 19  and the suspect drug BNT162b2 .
Patient awoke with a fever of 103.8 F  taken under his arm. We gave him Tylenol, Within 1 hour his temperature was 102.2. 3 hours later his temperature was 103.3, Gave Tylenol, again this went on until 9:00 pm 5/21/02.
15mo presents for follow up after inpatient stay for complex febrile seizure. Presented to facility febrile after short episode at home witnessed by babysitter (cold hands, perioral cyanosis, staring, drooling x20sec) and was subsequently admitted for ALTE vs febrile seizure. During admission she had a 5-10 minute tonic-clonic febrile seizure on pediatric ward (witnessed by resident) at facility, and then was transferred to PICU. She had no further fevers or seizures after she was transferred. She was discharged from the PICU later that afternoon (<12hrs later). Tmax since discharge was 100.1 measured 2 nights ago. PO intake has been normal. She has not had any cough/runny nose/diarrhea/vomiting/signs of illness. She does have a rash on her body that started the day of her first seizure and really began to get darker pink/red colored the day she was in the PICU, and is now fading. Mom insists that it is different appearing than her normal eczema breakouts. She was discharged from the PICU with Diastat, and a consult was placed for outpatient peds neurology consult. The febrile seizure occurred 10 days after her first MMR vaccine was given.
Felt some itchiness; Allergic reaction "hives" on both shoulders/Inside of right arm has more red marking hives, like small blisters/Hives disappeared overnight, then came back & includes neck this am/developed hives on chest/ Hives started coming and going; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Felt some itchiness) and URTICARIA (Allergic reaction "hives" on both shoulders/Inside of right arm has more red marking hives, like small blisters/Hives disappeared overnight, then came back & includes neck this am/developed hives on chest/ Hives started coming and going) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038A21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Mar-2021, the patient experienced URTICARIA (Allergic reaction "hives" on both shoulders/Inside of right arm has more red marking hives, like small blisters/Hives disappeared overnight, then came back & includes neck this am/developed hives on chest/ Hives started coming and going). On 28-Mar-2021, the patient experienced PRURITUS (Felt some itchiness). At the time of the report, PRURITUS (Felt some itchiness) and URTICARIA (Allergic reaction "hives" on both shoulders/Inside of right arm has more red marking hives, like small blisters/Hives disappeared overnight, then came back & includes neck this am/developed hives on chest/ Hives started coming and going) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant information was reported. Treatment information was not reported.
Muscle pain; Headacxhe; Tiredness; Upset stomach; Assthma flare up; This case was reported by a consumer via call center representative and described the occurrence of muscle pain in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced muscle pain, headache, tiredness, upset stomach and asthma aggravated. On an unknown date, the outcome of the muscle pain, headache, tiredness, upset stomach and asthma aggravated were unknown.   It was unknown if the reporter considered the muscle pain, headache, tiredness, upset stomach and asthma aggravated to be related to Shingrix.     Additional Information: GSK receipt date: 19-JAN-2023 Reporter Comment: The reporter reported that, the patient received Shingrix vaccine and experienced side effects such as muscle pain, headache, tiredness, upset stomach, asthma flare up. The reporter did not consent to follow up. The reporter asked how long the side effects of the shingles vaccine last.
Patient received Pneumovax 23 on 9/3/19. patient has severe redness and swollen at the injection site on 9/4/19. patient went to Urgent care to seek treatment. Patient received prescriptions prednisone 10mg and Tylenol OTC. Patient presented to the pharmacy on 9/5/19. The injection site is still red and swollen.
Existing overactive vagus response triggered. Happens about 1 of every 10 injections since I was young.